Modern Diagnostic IPO Subscription Window Closes Today
January 2, 2026, is the day when the last opportunity to buy shares of the Modern Diagnostic & Research Centre’s IPO is! A three-day period for subscriptions started on December 31, 2025, and the numbers are amazing. The investors have responded in such a way that the issue has been oversubscribed by 28.77 times in all categories.
It doesn’t matter if you are a retail investor or an institutional one; the hype indicates that everyone wants to be a part of the pathology and radiology chain. If you have not applied yet, hurry up, this could be a chance for you to be among the crowd and ride the IPO wave.
Modern Diagnostic IPO: Key Highlights And Investor Response
| Category | Details |
|---|---|
| Investor Demand | NIIs oversubscribed 39.61 times, retail investors 33.85 times, QIBs 8.94 times (as of Day 2) |
| IPO Size & Structure | Fresh issue of 4.1 million equity shares, raising ₹36.89 crore; no offer-for-sale component |
| Price Band & Lot Size | ₹85–90 per share; lot size 1,600 shares; two lots cost ₹2.88 lakh at upper price band |
| Allotment & Listing | Basis of allotment expected on Jan 5, 2026; shares credited Jan 6; BSE SME listing tentatively Jan 7 |
| Use of IPO Proceeds | ₹20.7 crore for medical equipment, ₹8 crore for working capital, ₹1 crore for debt repayment, remainder for general corporate purposes |
Grey Market (GMP) Buzz: Modern Diagnostic IPO In High Demand
The Modern Diagnostic IPO is not only making headlines in the regular market but also in the grey market! On Thursday, January 2, the unlisted shares were said to be trading at ₹104 each, a tempting 15.56% premium over the IPO’s maximum price limit of ₹90. Can you believe it? The investors are now ready to pay more just to get early access. The increase in price denotes that the chain of pathology and radiology has attracted a lot of people and is believed to be very profitable. If you have been watching from the outside, the grey market movement is a very strong signal that this IPO is very popular!
Aishwarya is a journalism graduate with over three years of experience thriving in the buzzing corporate media world. She’s got a knack for decoding business news, tracking the twists and turns of the stock market, covering the masala of the entertainment world, and sometimes her stories come with just the right sprinkle of political commentary. She has worked with several organizations, interned at ZEE and gained professional skills at TV9 and News24, And now is learning and writing at NewsX, she’s no stranger to the newsroom hustle. Her storytelling style is fast-paced, creative, and perfectly tailored to connect with both the platform and its audience. Moto: Approaching every story from the reader’s point of view, backing up her insights with solid facts.
Always bold with her opinions, she also never misses the chance to weave in expert voices, keeping things balanced and insightful. In short, Aishwarya brings a fresh, sharp, and fact-driven voice to every story she touches.
The post Last Chance To Subscribe: Modern Diagnostic IPO Sparks Massive Investor Rush appeared first on NewsX.
Comments are closed.